Uhmontpellier
Montpellier, 34295, France
NCT Number: NCT04448626
Chronic Obstructive Pulmonary Disease (COPD) is characterized by persistent airway obstruction and inflammatory response of the lungs and bronchi. Episodes of exacerbations contribute to increase the severity and prognosis of the disease. Muscle dysfunction (loss of strengh and muscle mass) is one of comorbidities affecting 30% to 60% of patients and playing a key role in their prognosis. During exacerbation, some studies have suggested an association between muscle dysfunction and modifications of inflammatory circulating factors such as CRP, TNF-alpha, IL- 6, IL8, but no exhaustive study has identified precisely one (or more) biomarker(s) that can induce this muscle wasting during the exacerbation of COPD. Our hypothesis is that the serum of exacerbated COPD patients represents a deleterious microenvironment for the muscle cells which would amplify the mechanisms of atrophy linked to hospitalization. Our team has already developed a cell culture model to study the effects of the plasma microenvironment on atrophy of cultured myotubes. The investigators have shown that the serum of COPD patients can induce muscle atrophy.
The objectives of this study are : 1/ to evaluate the effects of circulating pro-inflammatory factors on atrophy and the myogenic capacities of muscle cells; and 2/ to identify one (or more) circulating biomarker (s) that may be responsible for the muscle damage induced by the microenvironment of hospitalized patients for exacerbation of COPD. First, myotubes and myoblasts of healthy subjects will be cultivated with 9 exacerbation copd patient serum or 9 copd patient serum or 9 healthy subject serum. Myotube diameters, atrophy, inflammatory and oxidative stress markers and alteration of the myogenic capacity of satellite cells will be compared between three groups. Second, the differential expression of circulating proinflammatory molecules will be compared in the serum of the three groups. Identifying circulating factors associated with muscle weakness is a necessary step to better understand the mechanisms and consider a personalized therapeutic approach that can improve the functional and clinical prognosis of disease.
.
Looking for future studies?
Notify Me40 year–85 year
All sexes
Observational
Montpellier, 34295, France
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
1/ for COPD patients hospitalized for exacerbation:
Exclusion criteria
Time frame: 6 months
Atrophy marker evaluation in cultured muscle cells (myotubes)
Time frame: 6 months
Myogenic capacities of cultured muscle cells (myoblastes)
Time frame: 3 months
Identification of one (or more) circulating biomarker (s) that may be responsible for the muscle alteration induced by the microenvironment of patient in exacerbation of COPD
University Hospital, Montpellier
Other
Micro-environment Involvement in Muscle Alteration Induced by Copd Exacerbation
Acronym: MicAMI-BPCO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01624792
Atrophy, Chronic Disease
College Station, Texas, United States
View Trial DetailsNCT00435708
Chronic Disease, Chronic Obstructive Pulmonary Disease
Belfast, Co.Antrim, United Kingdom
View Trial DetailsNCT01832961
Chronic Disease, Chronic Obstructive Pulmonary Disease
London, United Kingdom
View Trial DetailsNCT00959855
Chronic Disease, Chronic Obstructive Pulmonary Disease
Beaumont, Dublin, Ireland
View Trial Details